Human papillomavirus-positive oropharyngeal cancer is a type of head and neck cancer caused by HPV infection, primarily affecting the throat, base of the tongue, and tonsils. The disease accounts for a significant proportion of oropharyngeal cancers globally, with India’s HPV-related cancer cases projected to rise to 121,302 by 2025. There is a high unmet clinical need for better therapies as current options, such as surgery, radiation, and chemotherapy, have limitations. A growing focus on immunotherapy and targeted treatments is expected to drive advancements in the drug pipeline, offering hope for improved patient outcomes and a higher quality of life.
Major companies involved in the human papillomavirus-positive oropharyngeal cancer pipeline drugs market include Nykode Therapeutics ASA, Merck Sharp & Dohme LLC, and others.
Leading drugs currently under the pipeline include Balstilimab, Cisplatin, Durvalumab, Tremelimumab, and others.
The growth of the human papillomavirus-positive oropharyngeal cancer drug pipeline is driven by rising incidence rates, high unmet clinical needs, advancements in immunotherapy, along with an increasing focus on developing targeted, effective, and less invasive treatment options.
The Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into human papillomavirus-positive oropharyngeal cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for human papillomavirus-positive oropharyngeal cancer. The human papillomavirus-positive oropharyngeal cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The human papillomavirus-positive oropharyngeal cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with human papillomavirus-positive oropharyngeal cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to human papillomavirus-positive oropharyngeal cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Human papillomavirus-positive oropharyngeal cancer is a subset of head and neck cancers caused by persistent infection with high-risk HPV strains, primarily HPV-16. It develops in the oropharynx, including the tonsils and base of the tongue, due to viral integration into host cells, leading to uncontrolled cell growth. The disease is more prevalent in younger, non-smoking individuals and is linked to changing lifestyle factors and sexual behavior.
Human papillomavirus-positive oropharyngeal cancer is treated using surgery, radiation therapy, and chemotherapy. However, these approaches often result in significant side effects and limited long-term effectiveness. Emerging therapies, such as immunotherapy and precision-targeted drugs, aim to improve survival rates while reducing toxicity. Ongoing clinical trials are focused on developing novel treatment modalities, including HPV-targeted vaccines and combination therapies, to address the high unmet medical need in managing this condition.
Human papillomavirus-positive oropharyngeal cancer is increasingly prevalent globally, with 29,000 new cases annually, accounting for 30% of total oropharyngeal cancer cases. In India, HPV-related cancers are projected to reach 121,302 by 2025, with oropharyngeal cancer representing 63.2% of HPV-related cancers. Regions like North America and Northern Europe have seen rising HPV+ oropharyngeal cancer cases, driven by decreased smoking and changing sexual behaviors, emphasizing the need for vaccination and screening initiatives.
This section of the report covers the analysis of human papillomavirus-positive oropharyngeal cancer drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total human papillomavirus-positive oropharyngeal cancer clinical trials.
The drug molecule categories covered under the human papillomavirus-positive oropharyngeal cancer pipeline analysis include small molecules, gene therapies, and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for human papillomavirus-positive oropharyngeal cancer.
The EMR human papillomavirus-positive oropharyngeal cancer report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Human Papillomavirus-Positive Oropharyngeal Cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for human papillomavirus-positive oropharyngeal cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of human papillomavirus-positive oropharyngeal cancer drug candidates.
The Phase III trial, sponsored by Weill Medical College of Cornell University, examines the efficacy of the nine-valent HPV vaccine's efficacy in preventing persistent oral HPV infection in men living with HIV. The study involves 700 participants and is expected to be completed by April 2026. This randomized, double-blinded trial aims to address HPV-associated oropharyngeal cancer risks.
The M.D. Anderson Cancer Center is conducting a Phase 2 study investigating Balstilimab (AGEN2034) for its ability to clear HPV in plasma cfDNA of HPV-positive oropharyngeal cancer patients after definitive therapy. This interventional study, with an estimated 20 participants, focuses on viral clearance and long-term outcomes. The study is anticipated to be completed by February 15, 2028 and promises advancements in immunotherapy.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Human Papillomavirus-Positive Oropharyngeal Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for human papillomavirus-positive oropharyngeal cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within human papillomavirus-positive oropharyngeal cancer pipeline insights.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share